Literature DB >> 33448693

Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy.

Takeo Ishii1,2, Tomohiro Kumagae1,3, Hiromichi Wakui1, Shingo Urate1, Shohei Tanaka1, Eriko Abe1, Toru Suzuki1, Takahiro Yamaji1, Sho Kinguchi1, Ryu Kobayashi1, Kotaro Haruhara1, Takashi Nakamura4, Shuzo Kobayashi1,3, Kouichi Tamura1.   

Abstract

Xanthine oxidoreductase (XOR) is a critical enzyme in purine metabolism and uric acid production, and its levels are reported to increase during stress, thereby promoting organ damage. Herein, we investigated the activity of XOR in a mouse model of aristolochic acid I (AA)-induced nephropathy, a type of nephrotoxic chronic kidney disease (CKD). A persistent decrease in renal function was observed in mice up to 4 weeks after 4 weeks of AA (2.5 mg kg-1 ) administration. Renal histology revealed an increase in tubular interstitial fibrosis over time. Although AA administration did not change XOR activity in the plasma, heart, liver, or muscle, XOR activity was persistently increased in renal tissue. Our results suggest that the renal tissue-specific increase in XOR activity is involved in the progression of tubulo-interstitial disorders, specifically fibrosis.
© 2021 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Entities:  

Keywords:  aristolochic acid; mouse model; nephropathy; xanthine oxidoreductase

Mesh:

Substances:

Year:  2021        PMID: 33448693      PMCID: PMC7876505          DOI: 10.1002/2211-5463.13083

Source DB:  PubMed          Journal:  FEBS Open Bio        ISSN: 2211-5463            Impact factor:   2.792


  43 in total

Review 1.  Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase.

Authors:  R Hille; T Nishino
Journal:  FASEB J       Date:  1995-08       Impact factor: 5.191

2.  Uric Acid Is a Strong Risk Marker for Developing Hypertension From Prehypertension: A 5-Year Japanese Cohort Study.

Authors:  Masanari Kuwabara; Ichiro Hisatome; Koichiro Niwa; Shigeko Hara; Carlos A Roncal-Jimenez; Petter Bjornstad; Takahiko Nakagawa; Ana Andres-Hernando; Yuka Sato; Thomas Jensen; Gabriela Garcia; Bernardo Rodriguez-Iturbe; Minoru Ohno; Miguel A Lanaspa; Richard J Johnson
Journal:  Hypertension       Date:  2017-12-04       Impact factor: 10.190

3.  Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity.

Authors:  Shih-Yu Chang; Elijah J Weber; Viktoriya S Sidorenko; Alenka Chapron; Catherine K Yeung; Chunying Gao; Qingcheng Mao; Danny Shen; Joanne Wang; Thomas A Rosenquist; Kathleen G Dickman; Thomas Neumann; Arthur P Grollman; Edward J Kelly; Jonathan Himmelfarb; David L Eaton
Journal:  JCI Insight       Date:  2017-11-16

Review 4.  Stressing out the mitochondria: Mechanistic insights into NLRP3 inflammasome activation.

Authors:  Monica Yabal; Dale J Calleja; Daniel S Simpson; Kate E Lawlor
Journal:  J Leukoc Biol       Date:  2018-12-27       Impact factor: 4.962

5.  Burden of Care and Quality of Life Among Caregivers for Adults Receiving Maintenance Dialysis: A Systematic Review.

Authors:  Elise L Gilbertson; Rathika Krishnasamy; Celine Foote; Alice L Kennard; Meg J Jardine; Nicholas A Gray
Journal:  Am J Kidney Dis       Date:  2018-11-16       Impact factor: 8.860

6.  Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines.

Authors:  S Page; D Powell; M Benboubetra; C R Stevens; D R Blake; F Selase; A J Wolstenholme; R Harrison
Journal:  Biochim Biophys Acta       Date:  1998-07-23

7.  Xanthine oxidoreductase activity assay in tissues using stable isotope-labeled substrate and liquid chromatography high-resolution mass spectrometry.

Authors:  Takayo Murase; Mai Nampei; Mitsuru Oka; Naoki Ashizawa; Koji Matsumoto; Atsushi Miyachi; Takashi Nakamura
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-11-25       Impact factor: 3.205

8.  Renal tubule angiotensin II type 1 receptor-associated protein promotes natriuresis and inhibits salt-sensitive blood pressure elevation.

Authors:  Hiromichi Wakui; Kazushi Uneda; Kouichi Tamura; Masato Ohsawa; Kengo Azushima; Ryu Kobayashi; Kohji Ohki; Toru Dejima; Tomohiko Kanaoka; Yuko Tsurumi-Ikeya; Miyuki Matsuda; Kotaro Haruhara; Akira Nishiyama; Machiko Yabana; Tetsuya Fujikawa; Akio Yamashita; Satoshi Umemura
Journal:  J Am Heart Assoc       Date:  2015-03-19       Impact factor: 5.501

9.  Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation.

Authors:  Annette Ives; Johji Nomura; Fabio Martinon; Thierry Roger; Didier LeRoy; Jeffrey N Miner; Gregoire Simon; Nathalie Busso; Alexander So
Journal:  Nat Commun       Date:  2015-03-24       Impact factor: 14.919

10.  Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice.

Authors:  Maimaiti Yisireyili; Motoharu Hayashi; Hongxian Wu; Yasuhiro Uchida; Koji Yamamoto; Ryosuke Kikuchi; Mohammad Shoaib Hamrah; Takayuki Nakayama; Xian Wu Cheng; Tadashi Matsushita; Shigeo Nakamura; Toshimitsu Niwa; Toyoaki Murohara; Kyosuke Takeshita
Journal:  Sci Rep       Date:  2017-04-28       Impact factor: 4.379

View more
  2 in total

1.  Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy.

Authors:  Shinya Taguchi; Kengo Azushima; Takahiro Yamaji; Shingo Urate; Toru Suzuki; Eriko Abe; Shohei Tanaka; Shunichiro Tsukamoto; Daisuke Kamimura; Sho Kinguchi; Akio Yamashita; Hiromichi Wakui; Kouichi Tamura
Journal:  Sci Rep       Date:  2021-12-08       Impact factor: 4.379

Review 2.  Aristolochic acid nephropathy: A scientometric analysis of literature published from 1971 to 2019.

Authors:  Hongjian Ji; Jingyin Hu; Guozhe Zhang; Jianxiang Song; Xiaohua Zhou; Dean Guo
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.